Wittycell's adjuvant products are developed in accordance with specifications similar to those used for drugs (see Guidelines on vaccine adjuvants for human use, EMEA / CHMP). However, Adjuvants are not considered as a separate entity, but as components of a specific vaccine. It is therefore impossible to separate the adjuvant and vaccine markets.
The Wittycell Strategy
- Development of new iNKT agonists for adjuvant use, using our technology platforms
- Determination of the Immunomodulatory properties of these new adjuvants
- Develop the Regulatory package including scale up, GMP batch, toxicity, and stability
- Enter into a Phase I/IIa clinical trial in HBV under a first right of access agreement
- Agreement with Vaccine companies for Sublicensing and/or M&A
- Develop new therapeutic vaccines against cancer and infectious diseases
Designed by Haute Mer